NewAmsterdam Pharma Company N.V. (NAMS)
| Market Cap | 2.79B -7.3% |
| Revenue (ttm) | 7.12M -88.9% |
| Net Income | -259.50M |
| EPS | -2.14 |
| Shares Out | 119.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,869,259 |
| Open | 22.91 |
| Previous Close | 22.58 |
| Day's Range | 22.13 - 23.73 |
| 52-Week Range | 21.02 - 42.21 |
| Beta | 0.09 |
| Analysts | Strong Buy |
| Price Target | 50.82 (+117.93%) |
| Est. Earnings | Nov 4, 2026 |
About NAMS
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartere... [Read more]
Financial Performance
In 2025, NAMS's revenue was $22.50 million, a decrease of -50.61% compared to the previous year's $45.56 million. Losses were -$203.82 million, -15.64% less than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for NAMS stock is "Strong Buy." The 12-month stock price target is $50.82, which is an increase of 117.93% from the latest price.
News
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile-
NewAmsterdam Pharma Company Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Obicetrapib demonstrates robust LDL reduction, safety, and additional metabolic benefits, with pivotal PREVAIL trial data expected soon. European launch is imminent, and U.S. commercialization will be informed by evolving market dynamics. Alzheimer’s research is advancing with a new phase IIb trial and substudy integration.
NewAmsterdam Pharma Company Transcript: Wells Fargo 21st Annual Healthcare Conference
Obicetrapib, a differentiated CETP inhibitor, is nearing key readouts from the PREVAIL cardiovascular outcomes trial and RUBIN diabetes study, with plans for launch in 12–18 months. PREVAIL’s interim analysis is set for Q4, focusing on robust LDL-lowering and additional benefits for diabetes and Alzheimer’s, positioning the drug uniquely in a growing market.
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical comp...
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
NAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...
NewAmsterdam Pharma price target lowered to $50 from $51 at RBC Capital
RBC Capital lowered the firm’s price target on NewAmsterdam Pharma (NAMS) to $50 from $51 and keeps an Outperform rating on the shares.
NewAmsterdam Pharma Company Transcript: Investor Day 2026
PREVAIL is powered for a 15% MACE reduction, with interim analysis in late 2024 and final readout in 2027. Obicetrapib's robust efficacy, safety, and unique biomarker effects support optimism for approval and commercial success, with REMBRANDT, RUBENS, and SPINOZA trials advancing key differentiation.
NewAmsterdam Pharma Company Slides: FY 2026
NewAmsterdam Pharma Company has posted slides in relation to its FY 2026 quarterly earnings report, which was published on August 5, 2026.
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 – – Topl...
NewAmsterdam Pharma Company Quarterly report: Q2 2026
NewAmsterdam Pharma Company has published its Q2 2026 quarterly earnings report on August 5, 2026.
NewAmsterdam Pharma Company Earnings release: Q2 2026
NewAmsterdam Pharma Company released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
NAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...
NewAmsterdam announces positive CHMP opinion for Ubeslo and Evlarco
NewAmsterdam Pharma (NAMS) along with partner Menarini Group announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommend...
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
- Positive CHMP opinion supports potential commercialization of obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combination in Europe - - Recommendation based on positive Phase 3 BROADWAY...
NewAmsterdam Pharma initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of NewAmsterdam Pharma (NAMS) with an Outperform rating and $58 price target The firm’s cited a few reasons for its positive outlook, including obicetrapib’s ability to…
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
NAARDEN, the Netherlands and MIAMI, July 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...
NewAmsterdam Pharma price target raised to $51 from $47 at RBC Capital
RBC Capital raised the firm’s price target on NewAmsterdam Pharma (NAMS) to $51 from $47 and keeps an Outperform rating on the shares. The firm’s patient survey suggests strong unmet…
NewAmsterdam Pharma Company Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
PREVAIL's interim analysis is set for year-end, with results expected in Q1, aiming for early completion if efficacy endpoints are met. Lower event rates and updated MACE definitions support trial power, while commercial prospects are strong due to broad benefits and expanded guidelines.
NewAmsterdam Pharma Company Transcript: Jefferies Global Healthcare Conference 2026
Significant progress includes lower-than-expected event rates in pivotal trials, strong safety and efficacy signals, and a robust cash position to support launch and pipeline growth. Interim analysis for PREVAIL may allow early completion, with further data and commercial updates expected at the next investor event.
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions
NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
NAARDEN, the Netherlands and MIAMI, May 28, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compan...
NewAmsterdam Pharma Company Transcript: RBC Capital Markets Global Healthcare Conference 2026
PREVAIL's design was updated to a modern 4-point MACE definition and increased event targets for robust efficacy, with interim analysis requiring significance in both 3- and 4-point MACE. Regulatory alignment and strong ancillary benefits position obicetrapib for broad adoption.
NewAmsterdam Pharma Company Transcript: Bank of America Global Healthcare Conference 2026
Phase III data show strong LDL and Lp(a) reductions, with additional benefits in diabetes and early Alzheimer's signals. Interim PREVAIL results are expected Q1 next year, with broad market potential driven by evolving guidelines and a large unmet need.
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
NAARDEN, the Netherlands and MIAMI, May 11, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compan...